Valeant faces PhRMA attack, will discuss fraud allegation

PhRMA posted an Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX), saying the company's "strategy is more reflective of a hedge fund than an innovative biopharmaceutical company." The article, by PhRMA SVP of Communications Robert Zirkelbach, contrasted Valeant's business model with those